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PROTECT carotid artery stenting study
Thomas L. Forbes, London, Ontario, CanadaEarly results of the PROTECTed Carotid Artery Stent-
ing in Subjects at High Risk for Carotid Endarterectomy
(PROTECT) Study were recently presented at the 2009
International Stroke Conference of the American Heart
Association (San Diego, Calif, Feb 18-20, 2009).1
This study included patients from 34 centers recruited
between 2006 and 2008 and assessed a new embolic pro-
tection device, Emboshield Pro (Abbott Laboratories, Ab-
bott Park, Ill), used with the Xact stent (Abbott). Study
participants were required to be at high risk for endarterec-
tomy (CEA). High-risk criteria included contralateral in-
ternal carotid artery (ICA) occlusion, post-CEA restenosis,
ejection fraction 35%, and age 80 years. Participants
were restricted to those with 50% symptomatic ICA
stenoses or 80% asymptomatic lesions. Investigators re-
ported the early (30-day) results of the first 220 patients.
Most of the patients weremen (64%). Themean patient
age was 72.5 years, and 29.5% were aged 80 years.
Comorbidities included coronary artery disease (71%), pre-
vious coronary artery bypass grafting (29%), left ventricular
dysfunction (25%), hypertension (89%), dyslipidemia
(90%), prior CEA (23%), and contralateral ICA occlusion
(13%). The mean degree of lesion stenosis was 73.5% and
the mean stenosis length was 18 mm.
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1618Device success (50% residual stenosis) was achieved
in 98.6% of patients. Within 30 days of the procedure, there
were three minor strokes, one death, and one myocardial
infarction, for a composite rate of stroke or death of 1.8%
(95% confidence interval [CI], 0.5-4.6). The composite
rate of stroke, death, or myocardial infarction was 2.3%
(95% CI, 0.7-5.2), and rate of transient ischemic attack was
3.6%.
The trial investigators concluded that primary out-
come event rates were low, and when compared with the
SECURITY (Study to Evaluate the Neurosheild Bare
Wire Cerebral Protection System and Xact Stent in Pa-
tients at High Risk for Carotid Endarterectomy) and
ARCHeR (ACCULINK for Revascularization of Ca-
rotids in High-Risk Patients) registries, the composite
event rates were lower in the PROTECT study. They
propose that this may be due to greater experience and
improved patient selection.
COMMENTARY
A low rate of periprocedural neurologic events, myo-
cardial infarctions, and deaths was achieved in this study of
stenting in high-risk symptomatic and asymptomatic pa-
tients. This is commendable, but the applicability to one’s
practice remains unclear.
High-risk status remains somewhat subjective and vari-
able among the different studies and registries, making
comparison difficult. In addition, the advantage of any
intervention in high-risk patients remains uncertain with
the absence of a medically treated comparative group.
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